NCT02657551View on ClinicalTrials.gov

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Thyroid Cancer
Interventions
DRUG

Regorafenib

Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.

Trial Locations (2)

06520-8028

Yale Cancer Center, New Haven

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02657551 - A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer | Biotech Hunter | Biotech Hunter